1110-P: Use of IDegLira Is Associated with High Persistency Rates Up to 12 Months (M) and Improved A1C after 6M in Swedish Clinical Practice
| Autor: | Jan Ekelund, Björn Eliasson, Ann-Marie Svensson, Joao Diogo Da Rocha Fernandes, Mervete Miftaraj, Ann-Charlotte Mårdby |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Insulin degludec Pediatrics medicine.medical_specialty Index date business.industry Liraglutide Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Retrospective cohort study Type 2 diabetes medicine.disease Clinical Practice 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Cohort Internal Medicine Medicine business Body mass index medicine.drug |
| Zdroj: | Diabetes. 68 |
| ISSN: | 1939-327X 0012-1797 |
| Popis: | This retrospective study examines outcomes associated with use of IDegLira - a fixed-ratio insulin degludec/liraglutide combination - in a large real-world cohort of patients with type 2 diabetes in Sweden. Data were obtained from the Swedish National Diabetes Registry on patients who initiated IDegLira (index date) until the end of 2017 (or 30 June/1 January 2017 for 6M/12M for persistency analyses). Persistency at 6M was defined as ≥1 more IDegLira withdrawal within 6M of index date, and 12M persistency was ≥1 more withdrawal in M6-12. Clinical variables were assessed at baseline (closest measurement to index date in previous 12M) and 6M ± 45 days after IDegLira initiation. Mean daily IDegLira dose was calculated from volume withdrawn during defined time periods of ≥6M. Baseline characteristics for overall cohort (N=3000) are in Table. At 6 and 12M, 2281/2432 (94%) and 1482/1760 (84%) patients were persistent, respectively. In persistent patients, least squares mean [95% CI] change in A1C and body mass index was -0.9% [-1.0; -0.8] and -0.3 kg/m2 [-0.5; -0.2] at 6M, respectively and mean daily IDegLira dose was 32-35 U at all 180-day periods assessed (Table). After 6M, IDegLira use in Sweden is associated with improved A1C and no clinically significant change in BMI at a moderate mean daily insulin dose, and 84% were persistent at 12M. Disclosure B. Eliasson: Advisory Panel; Self; Amgen Inc., AstraZeneca, Merck Sharp & Dohme Corp. Speaker's Bureau; Self; Boehringer Ingelheim International GmbH. Other Relationship; Self; Eli Lilly and Company, Novo Nordisk A/S, Sanofi. J. Ekelund: Employee; Spouse/Partner; AstraZeneca. Stock/Shareholder; Spouse/Partner; AstraZeneca. A. Svensson: None. M. Miftaraj: None. A. Mårdby: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. J. da Rocha Fernandes: Employee; Self; Novo Nordisk A/S. Funding Novo Nordisk A/S |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|